News - Atrium Innovations announces that it has entered into a definitive arrangement agreement with a company backed by the Permira funds whereby the Permira funds will acquire all the issued and outstanding common shares of Atrium, other than the shares to be rolled over by Fonds de solidarité FTQ and Caisse de dépôt et placement du Québec, for $24.00 in cash per Share. Upon completion of the transaction, Atrium will be jointly owned by the Permira funds (75%), the Fonds (12.5%) and CDPQ (12.5%), before management equity programs.
News - The U.S. government has for the first time approved an adjuvanted vaccine to protect against H5N1 bird flu. The vaccine was made by Quebec City-based ID Biomedical, a subsidiary of pharmaceutical giant GlaxoSmithKline. The approval was announced by the Food and Drug Administration, which regulates vaccines in the United States. The vaccine will not be available commercially; it will be placed in the U.S. government’s emergency stockpile.
News - Filmmaker Anne De Lean has had migraines since she was a little girl. Her father, Jacques De Lean, MD, a neurologist in Quebec City, also suffers from the sometimes debilitating condition that affects 10 percent of all adults ages 18 to 65 worldwide.
News - A team of clinical researchers led by CHU de Québec has received CAN$10.5 million from Génome Québec, Genome Canada, CIHR, Genome Alberta and other partners to recruit 5,600 pregnant women in Canada to study the potential of using DNA sequencing alone or in a contingent model with first trimester serum markers as a non-invasive method for detecting birth defects. The four marker first trimester serum quadruple screen,1T-Quad (PAPP-A, Free beta hCG, AFP and PIGF) provided by PerkinElmer will be used by researchers to validate its use in a contingent model where women identified by the 1T-Quad screen as having an increased risk of fetal aneuploidy undergo analysis of cell-free circulating fetal DNA from a standard blood draw to better estimate their risk of Down syndrome or other trisomy.
News - Aeterna Zentaris announces that it has submitted a New Drug Application to the U.S. Food and Drug Administration for its ghrelin agonist, macimorelin acetate (AEZS-130). Phase 3 data have demonstrated that the compound has the potential to become the first orally-approved product that induces growth hormone release to evaluate adult growth hormone deficiency, with accuracy comparable to available intravenous and intramuscular testing procedures.
Press releases - Under the theme of “Better Performance Through Innovation”, the seventh edition of the Quebec City Healthcare Industry Forum (FISQ) will be held on December 4 at Espaces Dalhousie in Quebec City. Organized by Québec International, this major annual event draws 200 key actors from the healthcare sector. Based on true case studies, the program for the 2013 edition will emphasize how incorporating innovative solutions is essential to boosting efficiency and performance within the health and social services systems. Nicolas Marceau, Quebec’s Minister of Finance and the Economy, is slated to deliver the closing address.
News - This highly innovative genomic centre in pediatrics located at Sainte-Justine UHC, the largest mother-child university hospital centre in Canada, will contribute to the development of new solutions to diagnostic challenges in children with genetic diseases. The initiative will transform the quality of care made available to young patients and improve prevention efforts from early childhood. This Canadian first represents a tremendous source of hope for sick children and their families.
News - To encourage the development of technological businesses in Québec, the Anges Québec private investors network has entered into a privileged partnership agreement with Valeo Management, MSBi Valorisation, SOVAR and Univalor, technology transfer and commercialization companies derived from university research in Québec. This agreement will favour the sharing of expertise and the pooling of resources and financial and business networks to support innovative seed companies that commercialize technologies derived from university research.
News - Merck Canada announced yesterday the allocation of a total of $16 million in grants to Quebec’s four faculties of medicine. McGill, along with Université de Montréal, Université de Sherbrooke and Université Laval will each receive $4 M to support health research with a translational component conducted in areas of unmet medical need.
News - Researchers from Université Laval’s Faculty of Medicine and CHU de Québec have shown that it is possible to treat venous ulcers unresponsive to conventional treatment with wound dressings made from human skin grown in vitro. A study published recently in the journal Advances in Skin and Wound Care demonstrates how this approach was successfully used to treat venous lower-extremity ulcers in patients who had been chronically suffering from such wounds.